Codexis (CDXS) Releases Earnings Results, Beats Expectations By $0.08 EPS

Codexis (CDXS) reported quarterly earnings results on Tuesday, Aug-9-2016. The company said it had a profit of $0.12 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.08. Analysts had a consensus of $0.04. The company posted revenue of $16.00 million in the period, compared to analysts expectations of $15.10 million. The company’s revenue was up 166.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.14 EPS.

Codexis opened for trading at $4.16 and hit $4.35 on the upside on Monday, eventually ending the session at $4.28, with a gain of 2.15% or 0.09 points. The heightened volatility saw the trading volume jump to 60,702 shares. Company has a market cap of $175 M.

In a different news, on Nov 12, 2015, James Lalonde (SVP, R&D) sold 9,441 shares at $3.52 per share price. According to the SEC, on Sep 15, 2015, Patrick Y Yang (director) purchased 10,000 shares at $3.47 per share price. On Sep 11, 2015, Bernard J Kelley (director) sold 5,200 shares at $3.45 per share price, according to the Form-4 filing with the securities and exchange commission.

Codexis Inc. is a developer of biocatalysts. The Company is engaged in the pharmaceutical and fine chemical industries. The Company’s CodeEvolver protein engineering technology platform is used in the evolution and optimization of biocatalysts to perform specific and desired chemical reactions at commercial scale. The pharmaceutical customers use its technology products and services in their manufacturing process development and production of drugs. The Company’s technologies enable scale-up and implementation of biocatalytic solutions for sustainable process development from research to manufacturing. The Company’s products include Codex screening panels and kits that enable customers to establish optimal reactions. The Company’s pharmaceutical products include enzymes pharmaceutical intermediates and Codex Biocatalyst Kits and Panels.


Leave a Reply

Codexis - Is it time to Sell?

Top Brokerage Firms are advising their investors on Codexis. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.